Literature DB >> 22353256

Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.

Malin K B Jonsson1, Marc A Vos, Gary R Mirams, Göran Duker, Peter Sartipy, Teun P de Boer, Toon A B van Veen.   

Abstract

Human embryonic stem cell-derived cardiomyocytes (hESC-CM) have been proposed as a new model for safety pharmacology. So far, a thorough description of their basic electrophysiology and extensive testing, and mechanistic explanations, of their overall pro-arrhythmic ability is lacking. Under standardized conditions, we have evaluated the sensitivity of hESC-CM to proarrhythmic provocations by blockade of hERG and other channels. Using voltage patch clamp, some ion current densities (pA/pF) in hESC-CM were comparable to adult CM: I(Kr) (-12.5 ± 6.9), I(Ks) (0.65 ± 0.12), I(Na,peak) (-72 ± 21), I(Na,late) (-1.10 ± 0.36), and I(Ca,L) (-4.3 ± 0.6). I(f) density was larger (-10 ± 1.1) and I(K1) not existent or very small (-2.67 ± 0.3). The low I(K1) density was corroborated by low KCNJ2 mRNA levels. Effects of pro-arrhythmic compounds on action potential (AP) parameters and provocation of early afterdepolarizations (EADs) revealed that Chromanol293B (100 μmol/l) and Bay K8644 (1 μmol/l) both significantly prolonged APD(90). ATX-II (<1 μmol/l ) and BaCl(2) (10 μmol/l ) had no effect on APD. The only compound that triggered EADs was hERG blocker Cisapride. Computer simulations and AP clamp showed that the immature AP of hESC-CM prevents proper functioning of I(Na)-channels, and result in lower peak/maximal currents of several other channels, compared to the adult situation. Lack of functional I(K1) channels and shifted I(Na) channel activation cause a rather immature electrophysiological phenotype in hESC-CM, and thereby limits the potential of this model to respond accurately to pro-arrhythmic triggers other than hERG block. Maturation of the electrical phenotype is a prerequiste for future implementation of the model in arrhythmogenic safety testing.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22353256     DOI: 10.1016/j.yjmcc.2012.02.002

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  53 in total

1.  FutureTox II: in vitro data and in silico models for predictive toxicology.

Authors:  Thomas B Knudsen; Douglas A Keller; Miriam Sander; Edward W Carney; Nancy G Doerrer; David L Eaton; Suzanne Compton Fitzpatrick; Kenneth L Hastings; Donna L Mendrick; Raymond R Tice; Paul B Watkins; Maurice Whelan
Journal:  Toxicol Sci       Date:  2015-02       Impact factor: 4.849

2.  Contribution of potassium channels to action potential repolarization of human embryonic stem cell-derived cardiomyocytes.

Authors:  Yin Wang; Renjun Zhu; Leslie Tung
Journal:  Br J Pharmacol       Date:  2019-06-26       Impact factor: 8.739

3.  Using Light to Endow Stem-Cell-Derived Cardiomyocytes With Virtual IK1 Conductances.

Authors:  Teun P de Boer
Journal:  Biophys J       Date:  2018-10-30       Impact factor: 4.033

4.  Pluripotent stem cells as a platform for cardiac arrhythmia drug screening.

Authors:  Jordan S Leyton-Mange; David J Milan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

Review 5.  Evolution of strategies to improve preclinical cardiac safety testing.

Authors:  Gary Gintant; Philip T Sager; Norman Stockbridge
Journal:  Nat Rev Drug Discov       Date:  2016-02-19       Impact factor: 84.694

6.  Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells.

Authors:  Glenna C L Bett; Aaron D Kaplan; Agnieszka Lis; Thomas R Cimato; Emmanuel S Tzanakakis; Qinlian Zhou; Michael J Morales; Randall L Rasmusson
Journal:  Heart Rhythm       Date:  2013-09-19       Impact factor: 6.343

7.  ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.

Authors:  Michael R Hicks; Julia Hiserodt; Katrina Paras; Wakana Fujiwara; Ascia Eskin; Majib Jan; Haibin Xi; Courtney S Young; Denis Evseenko; Stanley F Nelson; Melissa J Spencer; Ben Van Handel; April D Pyle
Journal:  Nat Cell Biol       Date:  2017-12-18       Impact factor: 28.824

Review 8.  Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes.

Authors:  Xiulan Yang; Lil Pabon; Charles E Murry
Journal:  Circ Res       Date:  2014-01-31       Impact factor: 17.367

9.  Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery.

Authors:  Irene C Turnbull; Deborah K Lieu; Ronald A Li; Kevin D Costa
Journal:  Drug Discov Today Dis Models       Date:  2012-12-21

Review 10.  Marching towards regenerative cardiac therapy with human pluripotent stem cells.

Authors:  Kevin O Maher; Chunhui Xu
Journal:  Discov Med       Date:  2013-06       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.